PRESS RELEASE

published on 02/26/2022 at 18:05 from SANOFI-AVENTIS

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis